Artwork

محتوای ارائه شده توسط Dr. Jason Edwards. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Dr. Jason Edwards یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Player FM - برنامه پادکست
با برنامه Player FM !

Revolutionary Advancements in Blood Cancer Treatment with Dr. Mark Fesler

30:40
 
اشتراک گذاری
 

Manage episode 439356417 series 3599583
محتوای ارائه شده توسط Dr. Jason Edwards. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Dr. Jason Edwards یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

Discover the revolutionary advancements in blood cancer treatment with Dr. Mark Fesler, a leading hematologist and oncologist at St. Luke's. We promise you'll gain a comprehensive understanding of the intricate phases of clinical trials, from safety assessments to efficacy evaluations. Dr. Fesler sheds light on the transformative shift from traditional cytotoxic drugs to cutting-edge immunotherapies, including checkpoint inhibitors, chimeric antigen T cells, and the promising bispecific antibodies that are changing the landscape of cancer care.
Navigate the complexities of clinical trials through the lens of Nassim Nicholas Taleb's "Black Swan" concept, appreciating the delicate balance of risk and benefit in drug development. We'll uncover the significant breakthroughs in bispecific antibodies for blood cancers and discuss the ethical considerations of fast-tracking treatments for patients facing limited life expectancy. Additionally, we tackle the reproducibility crisis in clinical trials, highlighting the importance of reliable and robust findings in ensuring patient safety and treatment efficacy.
Look to the future as we explore the expanding potential of bispecific therapies beyond blood cancers to solid tumors like breast, prostate, and lung cancer. Dr. Fesler shares insights on ongoing clinical trials at St. Luke's and emphasizes the move towards outpatient treatments and earlier lines of therapy. Learn about the specific immune-related cancers that show promising responses to these therapies and find out how patients can get involved in these groundbreaking studies. Join us in celebrating the relentless efforts of healthcare professionals and researchers driving innovation and improving patient outcomes in hematology and oncology.

  continue reading

فصل ها

1. Advancements in Blood Cancer Treatment (00:00:00)

2. Risks and Benefits in Clinical Trials (00:11:21)

3. Expanding Use of Bispecific Therapies (00:22:29)

4. Advancing Hematology and Oncology (00:29:29)

11 قسمت

Artwork
iconاشتراک گذاری
 
Manage episode 439356417 series 3599583
محتوای ارائه شده توسط Dr. Jason Edwards. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Dr. Jason Edwards یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

Discover the revolutionary advancements in blood cancer treatment with Dr. Mark Fesler, a leading hematologist and oncologist at St. Luke's. We promise you'll gain a comprehensive understanding of the intricate phases of clinical trials, from safety assessments to efficacy evaluations. Dr. Fesler sheds light on the transformative shift from traditional cytotoxic drugs to cutting-edge immunotherapies, including checkpoint inhibitors, chimeric antigen T cells, and the promising bispecific antibodies that are changing the landscape of cancer care.
Navigate the complexities of clinical trials through the lens of Nassim Nicholas Taleb's "Black Swan" concept, appreciating the delicate balance of risk and benefit in drug development. We'll uncover the significant breakthroughs in bispecific antibodies for blood cancers and discuss the ethical considerations of fast-tracking treatments for patients facing limited life expectancy. Additionally, we tackle the reproducibility crisis in clinical trials, highlighting the importance of reliable and robust findings in ensuring patient safety and treatment efficacy.
Look to the future as we explore the expanding potential of bispecific therapies beyond blood cancers to solid tumors like breast, prostate, and lung cancer. Dr. Fesler shares insights on ongoing clinical trials at St. Luke's and emphasizes the move towards outpatient treatments and earlier lines of therapy. Learn about the specific immune-related cancers that show promising responses to these therapies and find out how patients can get involved in these groundbreaking studies. Join us in celebrating the relentless efforts of healthcare professionals and researchers driving innovation and improving patient outcomes in hematology and oncology.

  continue reading

فصل ها

1. Advancements in Blood Cancer Treatment (00:00:00)

2. Risks and Benefits in Clinical Trials (00:11:21)

3. Expanding Use of Bispecific Therapies (00:22:29)

4. Advancing Hematology and Oncology (00:29:29)

11 قسمت

All episodes

×
 
Loading …

به Player FM خوش آمدید!

Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.

 

راهنمای مرجع سریع